Regentis Biomaterials Advances GelrinC(R) as Potential First-in-Class Off-the-Shelf Knee Cartilage Repair Solution

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC(R) platform as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the United States, targeting a market estimated at approximately $3 billion. The company's technology aims to address the limitations of existing treatments by offering a single-step procedure that integrates into standard surgical workflows, eliminating the need for cell-based therapies or complex logistics.

Clinical data supporting GelrinC(R) demonstrate approximately 100% greater pain improvement compared to microfracture, a common surgical technique, with durable outcomes and MRI-confirmed regeneration of near-native cartilage. The procedure takes approximately 10 minutes and is associated with a recovery time of about two weeks, significantly shorter than cell-based alternatives. These factors are expected to drive adoption among surgeons, payers, and patients by reducing costs and simplifying treatment.

The U.S. market for knee cartilage repair encompasses approximately 470,000 annual cases, with no comparable ready-to-use competitor currently available. GelrinC(R) has already received CE Mark approval in Europe, and the company is advancing through a pivotal Phase III trial in the U.S. This positions Regentis for near-term catalysts, including potential commercialization and FDA submission. The product's off-the-shelf nature addresses a critical gap in orthopedic care, where current options often involve lengthy preparation times or limited efficacy.

Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions, with its Gelrin(TM) platform technology based on synchronized, degradable materials. The company's initial focus is on knee injuries and other orthopedic treatments, aiming to restore health and enhance quality of life through advanced biomaterials.

For more information on the company and its technologies, visit the InvestorBrandNetwork website for full terms of use and disclaimers at http://IBN.fm/Disclaimer. Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company's filings with the SEC, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Investors should not place undue reliance on these forward-looking statements, which are based on information available as of the date hereof.